CSIMarket
 
Nuwellis Inc   (NUWE)
Other Ticker:  
 
 
Price: $0.6988 $0.09 14.370%
Day's High: $0.77 Week Perf: -0.37 %
Day's Low: $ 0.64 30 Day Perf: 42.58 %
Volume (M): 2,697 52 Wk High: $ 8.20
Volume (M$): $ 1,885 52 Wk Avg: $2.18
Open: $0.66 52 Wk Low: $0.39



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Nuwellis Inc
Nuwellis Inc is a medical device company that specializes in developing and commercializing innovative therapies for patients with chronic heart failure and other fluid overload conditions. The company's flagship product, known as the Aquadex FlexFlow System, is a fluid management system that utilizes ultrafiltration to safely remove excess fluid from patients. This portable system allows patients to manage their fluid balance at home, reducing the need for hospitalization and improving their quality of life. Nuwellis Inc is dedicated to improving patient outcomes and creating more cost-effective solutions for fluid management in the healthcare industry.


   Company Address: 12988 Valley View Road Eden Prairie 55344 MN
   Company Phone Number: 345-4200   Stock Exchange / Ticker: NASDAQ NUWE
   NUWE is expected to report next financial results on March 02, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Nuwellis Partners with SeaStar Medical to Receive FDA Approval for Groundbreaking Pediatric Selective Cytopheretic Device, Quelimmune, and Raises $2.25 Million in Public Offering

Published Thu, Feb 22 2024 12:58 PM UTC



In a significant milestone for the medical technology sector, Nuwellis, Inc. has made headlines with a groundbreaking development. The company announced that its distribution partner, SeaStar Medical Holding Corporation, has received Humanitarian Device Exemption (HDE) from the U.S. Food and Drug Administration (FDA) for its innovative pediatric Selective Cytophere...

Stock Market Announcement

Nuwellis, Inc. Implements Inducement Grants to Support Growth Strategy Amid Fluid Overload Treatment Sector Expansion

Published Tue, Feb 20 2024 10:07 PM UTC



MINNEAPOLIS, Feb. 20, 2024 - Nuwellis, Inc. (Nasdaq: NUWE) disclosed today that it has sanctioned equity awards for two new employees under its 2021 Inducement Plan. The company's independent directors greenlit these awards as material inducements, complying with Nasdaq Listing Rule 5635(c)(4), which mandates public notification for equity awards not issued under a...

Clinical Study

Nuwellis Highlights Aquadex SmartFlow System with Groundbreaking Clinical Data and Symposium at Technology and Heart Failure Therapeutics Conference

Published Tue, Feb 20 2024 1:43 PM UTC

Nuwellis, a pioneering medical technology company, is set to unveil groundbreaking clinical data and host a satellite symposium at the upcoming Technology and Heart Failure Therapeutics Conference. The company will share three presentations, each of which will showcase the revolutionary capabilities of Nuwellis' Aquadex SmartFlow system.As a leading innovator in the medical ...

Product Service News

Revamping Fluid Overload Management in Liver Disease: The Innovative Potential of Aquadex Therapy.

Published Tue, Feb 6 2024 2:00 PM UTC

End-stage liver disease patients often encounter complications primarily due to fluid overload, which is a largely unavoidable symptom. Currently, diuretics are used to facilitate the removal of this excess fluid in the body; however, not all patients respond to these medications, fostering a need for alternative methods. According to a recent case series, Aquadex Therapy ha...

Product Service News

Nuwellis Revolutionizes Ultrafiltration Therapy with FDA-Cleared Dual Lumen Peripheral Catheter, Expanding Patient Access and Improving Outcomes

Published Thu, Jan 4 2024 8:05 PM UTC

Nuwellis Receives FDA Clearance for Dual Lumen Extended Length Peripheral Catheter, Expanding Peripheral Access for Ultrafiltration TherapyIn a recent press release, medical device company Nuwellis Inc announced that it has received FDA clearance for an additional Dual Lumen Extended Length Peripheral Catheter. This specialty catheter provides an alternative peripheral acces...






 

Nuwellis Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com